Genmab A/S (NASDAQ:GMAB) Receives $45.20 Average PT from Analysts

Genmab A/S (NASDAQ:GMAB - Get Free Report) has earned an average rating of "Hold" from the thirteen brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $45.20.

GMAB has been the topic of several research analyst reports. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Friday, September 20th. Royal Bank of Canada raised shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. BTIG Research increased their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, June 27th. Finally, Truist Financial dropped their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its stake in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after acquiring an additional 544 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after buying an additional 749 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S in the 1st quarter valued at $43,000. Barometer Capital Management Inc. acquired a new stake in Genmab A/S during the 4th quarter worth $121,000. Finally, Headlands Technologies LLC lifted its holdings in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock worth $129,000 after acquiring an additional 4,853 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Trading Up 0.4 %

GMAB stock traded up $0.09 during trading on Friday, hitting $23.49. 604,712 shares of the stock traded hands, compared to its average volume of 577,700. The stock has a market cap of $15.53 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 0.73 and a beta of 0.98. Genmab A/S has a one year low of $23.24 and a one year high of $35.88. The company has a 50 day simple moving average of $26.55 and a 200 day simple moving average of $27.53.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. As a group, analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.